Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03074357 · ClinicalTrials.gov registry record
Urine, DNA and Clinical Information Collection From Patients With Alport Nephropathy.
A clinical trial of Alport Nephropathy, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 68
- Enrollment target
- 1
- Study location
NCT03074357 is a study of Alport Nephropathy that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 68 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03074357, a study of Alport Nephropathy, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
This biomarker study is a follow-up to CPLATFRM2201. The goal of CBASICHR0005 is to collect another urine sample, interval clinical information, and an optional DNA sample from as many of the original 80 patients as possible. This new information will transform the data obtained in PLATFRM2201 from a cross-section to a temporal profile, which will (a) further enable the identification of biomarkers predictive of faster progression, and (b) satisfy the FDA's recommendation to perform "natural history studies" in rare diseases.
Conditions Studied
Study Locations (1)
Minnesota
- Novartis Investigative Site - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2017-04-04 |
| Est. Completion | 2018-03-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03074357
The ClinicalTrials.gov registry entry for NCT03074357 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alport Nephropathy appearing as the primary indexed condition, and to 0 interventions.
NCT03074357 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT03074357 about?
NCT03074357 is a clinical study titled "Urine, DNA and Clinical Information Collection From Patients With Alport Nephropathy.". This biomarker study is a follow-up to CPLATFRM2201. The goal of CBASICHR0005 is to collect another urine sample, interval clinical information, and an optional DNA sample from as many of the original 80 patients as possible. This new information will transform the data obtained in PLATFRM2201 from ...
What is the current status of trial NCT03074357?
This trial is currently completed. The enrollment target is 68 participants. The study started on 2017-04-04. Estimated completion is 2018-03-23.
What conditions does trial NCT03074357 study?
This clinical trial studies the following conditions: Alport Nephropathy.
Who is sponsoring clinical trial NCT03074357?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03074357 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.